Molnupiravir
Small moleculeexperimentalCOVID-19
Clinical trial activity
22 trials · 18 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
11
Phase 3
6
Phase 4
0
Earliest trial started Apr 10, 2020 (NCT04392219)
Timeline
Indications
Mechanism of action
- RNADISRUPTING AGENT
RNA disrupting agent
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C(=O)OC[C@H]1O[C@@H](n2cc/c(=N\O)[nH]c2=O)[C@H](O)[C@@H]1O- Mol. weight
- 329.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL4650320 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06551844 | Phase 2 | Sep 1, 2025 | Tropical Diseases Hospital, Ho Chi Minh City, University of Oxford |
| NCT06667700 | Phase 3 | Dec 21, 2024 | Merck |
| NCT06488300 | Phase 2 | Jul 1, 2024 | University of Oxford |
| NCT05818124 | Phase 1 | Aug 21, 2023 | Merck |
| NCT06816030 | Phase 1 | Jun 28, 2023 | Merck |
| NCT06615869 | Phase 1 | Jan 20, 2023 | Merck |
| NCT05648448 | Phase 2 | Dec 22, 2022 | University of Oxford |
| NCT05638672 | N/A | Dec 15, 2022 | Capital Medical University, China Academy of Chinese Medical Sciences, Kamuzu University of Health Sciences |
| NCT05559905 | Phase 2 | Nov 2, 2022 | Merck |
| NCT05459532 | Phase 3 | Aug 12, 2022 | Bill and Melinda Gates Foundation, University of the Witwatersrand |
| NCT05386758 | Phase 1 | Jun 29, 2022 | Merck |
| NCT05386589 | Phase 1 | Jun 14, 2022 | Merck |
| NCT05412173 | N/A | Apr 1, 2022 | Valenta Pharm JSC |
| NCT05648799 | N/A | Mar 17, 2022 | Geropharm, Yaroslavl Regional Clinical Hospital for Military Veterans |
| NCT05595824 | Phase 3 | Dec 1, 2021 | Moscow State Clinical Hospital №50, Promomed, LLC |
| NCT04939428 | Phase 3 | Aug 11, 2021 | Merck |
| NCT04575597 | Phase 2/Phase 3 (Phase 3) | Oct 19, 2020 | Merck |
| NCT04575584 | Phase 2/Phase 3 (Phase 3) | Oct 19, 2020 | Merck |
| NCT04746183 | Phase 1/Phase 2 (Phase 2) | Jul 3, 2020 | Moorgreen Hospital, Southampton, Royal Liverpool & Broadgreen University Hospitals NHS Truts, University of Cambridge, University of Liverpool |
| NCT04405570 | Phase 2 | May 26, 2020 | Ridgeback Biotherapeutics, LP |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 10 | 10 | 3 | 2020 |
| Ridgeback Biotherapeutics, LP | For profit | 3 | 3 | 2 | 2020 |
| University of Oxford | Academic/Hospital | 3 | 3 | 1 | 2022 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Geropharm | For profit | 1 | 1 | 1 | 2022 |
| Kamuzu University of Health Sciences | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Moorgreen Hospital, Southampton | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Moscow State Clinical Hospital №50 | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Promomed, LLC | For profit | 1 | 1 | 1 | 2021 |
| Royal Liverpool & Broadgreen University Hospitals NHS Truts | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Tropical Diseases Hospital, Ho Chi Minh City | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Cambridge | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Liverpool | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of the Witwatersrand | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Valenta Pharm JSC | For profit | 1 | 1 | 1 | 2022 |
| Yaroslavl Regional Clinical Hospital for Military Veterans | Government | 1 | 0 | 1 | 2022 |
18 organizations
Page 1 / 1